Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients

Acta Haematologica

Volumn 129, Issue 1, 2013, Pages 35-39

  Buda, Gabriele ^a   Orciuolo, Enrico ^a   Carulli, Giovanni ^a   Galimberti, Sara ^a   Ghio, Francesco ^a   Cervetti, Giulia ^a   Pelosini, Matteo ^a   Petrini, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Bone marrow transplant; Multiple myeloma; Thalidomide plus doxorubicin and dexamethasone; Thalidomide, bortezomib and dexamethasone

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT RESPONSE; COMPARATIVE STUDY; INDUCTION CHEMOTHERAPY; MINIMAL RESIDUAL DISEASE; RETROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RETROSPECTIVE STUDIES; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84867900057     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000339635     Document Type: Article

References (23)

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97 (Pubitemid 26240110)
2. Van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M: Complete response correlates with long-term survival and progression- free survival in high-dose therapy in multiple myeloma. Haematologica 2007; 92: 1399-1406 (Pubitemid 350144158)
3. Lahuerta JJ, Mateos MV, Martínez-López J, Rosiñol L, Sureda A, de la Rubia J, García- Laraña J, Martínez- Martínez R, Hernández- García MT, Carrera D, Besalduch J, de Arriba F, Ribera JM, Escoda L, Hernández-Ruiz B, García-Frade J, Rivas-González C, Alegre A, Bladé J, San Miguel JF: Influence of preand post-transplantation responses on outcome of patients with multiple myeloma: Sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008; 26: 5775-5782
4. Harousseau JL, Attal M, Avet-Loiseau H: The role of complete response in multiple myeloma. Blood 2009; 114: 3139-3146
5. Chanan-Kahn A, Giralt S: Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010; 28: 2612-2624
6. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, de Vivo A, Testoni N, Nicci C, Terragna C, Grafone T, Perrone G, Ceccolini M, Tura S, Baccarani M, Bologna 2002 study: Superiority of thalidomide and dexamethasone over vincristine-doxorubicinedexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35-39 (Pubitemid 40967171)
7. Macro M, Divine M, Uzunban Y: Dexamethasone + thalidomide compared to VAD as pre-transplant treatment in newly diagnosed multiple myeloma: A randomized trial (abstract 57). Blood 2006; 108: 22a.
8. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, Michallet M, Maisonneuve H, Benboubker L, Maloisel F, Petillon MO, Webb I, Mathiot C, Moreau P: Bortezomib- dexamethasone is superior to vincristine- doxorubicin-dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase 3 trial. J Clin Oncol 2010; 28: 4621-4629
9. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreutz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma R, Naumann R, Sinnige H, Blau I, Delforge M, de Weerdt O, Wijermans P, Wittebol S, Duersen U, Vellenga E, Goldschmidt H, Dutch-Belgian HOVON, German GMMG: Thalidomide in induction treatment increases the very good partial remission rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008; 93: 124-127
10. Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk- Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P, Dutch-Belgian Hemato-Oncology Group (HOVON): A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010; 115: 1113-1120
11. Morgan GJ, Davies FE, Owen RG: Thalidomide combinations improve response rates: Results from the MRC IX study (abstract 3593). Blood 2007; 110: 1051a.
12. Paiva B, Gutiérrez NC, Rosiñol L, Vídriales MB, Montalbán MÁ, Martínez-López J, Mateos MV, Cibeira MT, Cordón L, Oriol A, Terol MJ, Echeveste MA, de Paz R, de Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla J, Sureda A, Gorosquieta A, Alegre A, Martin A, Hernández MT, Lahuerta JJ, Bladé J, San Miguel JF, PETHEMA/GEM (Programa para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma) Cooperative Study Groups: Highrisk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012; 119: 687-691
13. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, International Myeloma Working Group: International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467- 1473 (Pubitemid 44264086)
14. Rawstron AC, Davies FR, Dasgupta R, Ashcroft J, Patmore R, Drayson MT, Owen RG, Jack AS, Child JA, Morgan GJ: Flow cytometric disease monitoring in multiple myeloma: The relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002; 100: 3095- 3100 (Pubitemid 35217054)
15. Cannizzo E, Carulli G, Del Vecchio L, Ottaviano V, Bellio E, Zenari E, Azzarà A, Petrini M, Preffer F: The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry. A new statistical model. Am J Clin Pathol 2012; 137: 377-386
16. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin AK, Omedé P, Pellat-Deceunynck C, Perez Andres M, Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, de Tute RM, Van Valckenborgh E, Weston-Bell N, Owen RG, San Miguel JF, Sonneveld P, Johnsen HE, European Myeloma Network: Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008; 93: 431-438 (Pubitemid 351398645)
17. Paiva B, Vidriales MB, Cerveró J, Mateo G, Pérez JJ, Montalbán MA, Sureda A, Montejano L, Gutiérrez NC, García de Coca A, de Las Heras N, Mateos MV, López-Berges MC, García-Boyero R, Galende J, Hernández J, Palomera L, Carrera D, Martínez R, de la Rubia J, Martín A, Bladé J, Lahuerta JJ, Orfao A, San Miguel JF, GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups: Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008; 112: 4017-4023
18. Willems P, Verhagen O, Segeren C, Veenhuizen P, Guikema J, Wiemer E, Groothuis L, Jong TB, Kok H, Bloem A, Bos N, Vellenga E, Mensink E, Sonneveld P, Lokhorst H, van Der Schoot E, Raymakers R: Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematology-Oncology Group. Blood 2000; 96: 63-70 (Pubitemid 30456451)
19. Galimberti S, Brizzi F, Mameli M, Petrini M: An advantageous method to evaluate IgH rearrangement and its role in minimal residual disease detection. Leuk Res 1999; 23: 921- 929 (Pubitemid 29460828)
20. Wang M, Giralt S, Delasalle K, Handy B, Alexanian R: Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 2007; 12: 235-239 (Pubitemid 46930250)
21. Moreau P, Avet-Loiseau H, Harousseau JL, Attal M: Current trends in autologous stem cell transplantation for myeloma in the era of novel therapies. J Clin Oncol 2011; 29: 1898- 1906
22. Moreau P, Attal M, Pégourié B, Planche L, Hulin C, Facon T, Stoppa AM, Fuzibet JG, Grosbois B, Doyen C, Ketterer N, Sebban C, Kolb B, Chaleteix C, Dib M, Voillat L, Fontan J, Garderet L, Jaubert J, Mathiot C, Esseltine D, Avet-Loiseau H, Harousseau JL, IFM 2005-01 study investigators: Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM2005-01 trial. Blood 2011; 117: 3041- 3044
23. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M, GIMEMA Italian Myeloma Network: Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study. Lancet 2010; 376: 2075-2085